SOPH Form 144: Proposed Sale of 6,160 Shares ($27.5K)

SOPHiA GENETICS SA insider filing notifies a proposed sale of 6,160 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/03/2025 and an aggregate market value of $27,535.20.

Rhea-AI Filing Summary

SOPHiA GENETICS SA insider filing notifies a proposed sale of 6,160 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/03/2025 and an aggregate market value of $27,535.20. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 and payment/settlement is shown as 10/02/2025. The filing also discloses recent 10b5-1 sales by Daan Guido Maria van Well totaling 4,996 shares sold on 07/07/2025, 07/21/2025, 07/23/2025, 08/19/2025, and 09/19/2025 with combined gross proceeds of $15,599.32. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SOPH Form 144 filed indicate?

The filer plans to sell 6,160 shares of SOPH common stock via Morgan Stanley Smith Barney LLC on approximately 10/03/2025 with an aggregate market value of $27,535.20.

How were the shares being sold acquired?

The 6,160 shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 and the filing lists the payment/settlement date as 10/02/2025.

Who is the broker handling the proposed sale?

The proposed sale is to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza, 8th Floor, New York, NY 10004 and will be on the NASDAQ.

Has the seller made recent sales of SOPH stock?

Yes. The filing lists recent 10b5-1 sales by Daan Guido Maria van Well totaling 4,996 shares with combined gross proceeds of $15,599.32 across five trades between 07/07/2025 and 09/19/2025.

Does the filing state any undisclosed material information?

By signing the notice, the person represents they do not know of any undisclosed material adverse information about the issuer; no additional material disclosures are included in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:37 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002006414
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SOPHIA GENETICS SA
SEC File Number	001-40627
Address of Issuer	La Piece 12 ch-1180 Rolle SWITZERLAND 00000
Phone	41216941060
Name of Person for Whose Account the Securities are To Be Sold	DAAN GUIDO MARIA VAN WELL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6160	27535.20	67579560	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/02/2025	Restricted Stock Units	Issuer			6160	10/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	09/19/2025	685	2174.94
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	08/19/2025	685	2349.69
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	07/23/2025	118	404.74
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	07/21/2025	684	2417.05
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	07/07/2025	2724	8252.90

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 10/02/2025 through 12/18/2025.
Date of Notice	10/03/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/09/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daan Guido Maria Van Well
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)